Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

ClinicalTrials.gov ID: NCT04040322

Public ClinicalTrials.gov record NCT04040322. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)

Study identification

NCT ID
NCT04040322
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Civi Biopharma, Inc.
Industry
Enrollment
198 participants

Conditions and interventions

Interventions

  • Placebo IV infusion Drug
  • Iloprost Injection, for intravenous use Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 13, 2019
Primary completion
Jun 8, 2021
Completion
Jun 8, 2021
Last update posted
May 24, 2025

2019 – 2021

United States locations

U.S. sites
30
U.S. states
19
U.S. cities
28
Facility City State ZIP Site status
Arizona Arthritis & Rheumatology Research, PLLC Phoenix Arizona 85032
Mayo Clinic - Scottsdale Scottsdale Arizona 85259
University of Arizona - Arthritis Research Center Tucson Arizona 85724
Cedars-Sinai Medical Center Los Angeles California 90048
University of California, Los Angeles Medical Center Los Angeles California 90059
Stanford University Medical Center Palo Alto California 94305
University of California San Francisco San Francisco California 94143
Georgetown University Medical Center - Department of Rheumatology Washington D.C. District of Columbia 20007
Northwestern Medical Faculty Foundation Chicago Illinois 60611
University Medical Center New Orleans New Orleans Louisiana 70112
Johns Hopkins University School of Medicine Baltimore Maryland 21224
Tufts Medical Center Boston Massachusetts 02111
University of Michigan Ann Arbor Michigan 48109-5422
West Michigan Rheumatology PLLC Grand Rapids Michigan 49546
University of Minnesota Maple Grove Minneapolis Minnesota 55369
University of Nebraska Medical Center Omaha Nebraska 68198
Robert Wood Johnson Medical School New Brunswick New Jersey 08903
Hospital for Special Surgery New York New York 10021
Columbia University Medical Center New York New York 10032
University of Cincinnati - Scleroderma Center Cincinnati Ohio 45267
Cleveland Clinic Cleveland Ohio 44195
Ohio State University Columbus Ohio 43210
The University of Toledo Medical Center (UTMC) - Ruppert Health Center Toledo Ohio 43614
University of Pennsylvania Philadelphia Pennsylvania 19104
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15261
Medical University of South Carolina (MUSC) Charleston South Carolina 29425
University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics Houston Texas 77030
University of Utah Salt Lake City Utah 84132
Virginia Mason Medical Center Seattle Washington 98101
Froedtert Hospital and the Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04040322, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 24, 2025 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04040322 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →